US cancer centers are overwhelmed with requests for daraxonrasib, an experimental therapy from Revolution Medicines, after Phase 3 trial results showed it doubled survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Dr. Daniel King, a medical oncologist at the Zuckerberg Cancer Center of Northwell Health, described a "deluge of patient requests" following the data release.
The FDA has now authorized compassionate use programs for daraxonrasib, allowing broader early access before formal approval. In the UK and Europe, patients must wait for clinical trial enrollment, though new studies are expected soon.
A separate US trial is already testing daraxonrasib as a first-line therapy, alone or with chemotherapy, at centers including Dana-Farber Cancer Institute in Boston.
Pancreatic cancer remains notoriously difficult to treat, and daraxonrasib, which also holds orphan drug designation from the European Medicines Agency, could become a critical new option for patients with advanced disease.